Evidence map›Paper›PMID 39588793›Full record

ArticleJournal of medical virology2024

Targeting HSP70-E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer.

Justin Garland, Showket Hussain, Rajani Rai, Amy L Kennedy, Zitha Redempta Isingizwe, Doris M Benbrook

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Justin GarlandDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0009-0002-3771-5248
Showket HussainDivision of Molecular Diagnostics and Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research, Noida, India.ORCID 0000-0003-1456-9217
Rajani RaiGynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0003-3503-5265
Amy L KennedyDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0002-7557-3909
Zitha Redempta IsingizweGynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0003-1403-0334
Doris M BenbrookDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0001-7606-8245

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Targeting HPV Consequences in a Cervical Cancer Clinical TrialR01CA200126 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA, MOORE, KATHLEEN N. · 2016 to 2021
$2.1M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA200126This research was funded by National Cancer Institute.
6 · The paper itself

Abstract

Cervical cancer is predominantly driven by persistent infections with high-risk human papillomavirus and the continuous activity of its E6 and E7 oncoproteins. This study explored the role of heat shock proteins 70 kDa (HSP70s) in enhancing the function of these oncoproteins and examined the impact of SHetA2, an investigational new drug, on this interaction. We found that HSP70 specifically binds to E7, but not E6, protein and that SHetA2 disrupts this binding. This disruption led to a significant reduction in E6 and E7 mRNA and E7 protein levels, while effects on E6 protein levels were minimal. SHetA2 treatment also resulted in altered levels of cell cycle regulatory proteins, reduced cell cycle progression, and decreased metabolic viability in cervical cancer cell lines and xenograft models. These findings support the potential of SHetA2 to impair cervical cancer progression by targeting HSP70/E7 interactions, highlighting its promise as a therapeutic strategy for treating cervical cancer.

Indexed as

HSP70 Heat-Shock ProteinsOncogene Proteins, ViralPapillomavirus E7 ProteinsUterine Cervical NeoplasmsAnimalsCell CycleCell Line, TumorFemaleHumansMiceProtein BindingRepressor ProteinsHSP70 Heat-Shock ProteinsOncogene Proteins, ViralPapillomavirus E7 ProteinsRepressor Proteinscervical cancerE7heat shock protein 70HPVHSP70human papillomavirusinvestigational new drugproteasomal degradationSHetA2

Identifiers

PMID39588793
PMCPMC11633939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.